Naloxon B. Braun (Naloxone Hydrochloride)

Naloxone, the active ingredient in Naloxon B. Braun, is an opioid antagonist presented as a sterile solution for intramuscular and intravenous use. It rapidly reverses opioid‑induced respiratory depression and restores normal breathing in patients experiencing opioid overdose.

GNH USA supplies Naloxon B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation, ensuring reliable access for emergency medical services and healthcare facilities across multiple continents.

Naloxone is used in the opioid pathway to rapidly reverse life‑threatening effects of opioid toxicity.

Opioid overdose: rapid reversal of respiratory depression and restoration of consciousness. Opioid‑induced respiratory depression: restores adequate breathing in acute settings. Acute opioid toxicity: normalizes vital signs and counteracts opioid effects.

Naloxone may cause a range of adverse reactions, most of which are related to sudden opioid withdrawal.

Common Side Effects: - Nausea - Vomiting - Sweating - Tachycardia - Hypertension - Agitation

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Pulmonary edema

When using Naloxon B. Braun, clinicians should observe several safety measures to minimise risks.

Assess airway and breathing: confirm adequate ventilation before administration. Monitor vital signs: observe heart rate, blood pressure and oxygen saturation continuously. Use only for confirmed opioid overdose: avoid unnecessary exposure in patients without opioid toxicity. Caution in cardiovascular disease: be aware of possible hypertension or tachycardia. Allergic reactions: discontinue if signs of hypersensitivity such as rash or anaphylaxis appear. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Naloxone can interact with other medications, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent high‑dose opioid therapy: may require repeated naloxone dosing and can precipitate severe withdrawal. - Mixed agonist‑antagonist opioids (e.g., buprenorphine): naloxone can block analgesic effects and cause abrupt withdrawal.

Moderate Interactions (Monitor Closely): - Benzodiazepines: combined use may still result in sedation despite opioid reversal. - Tricyclic antidepressants: increased risk of seizures when naloxone is administered. - MAO inhibitors: may enhance cardiovascular responses such as hypertension.